In solid tumors, neoadjuvant or adjuvant immune checkpoint blockade increases treatment-related grade 3 or 4 adverse events

Ann Intern Med. 2024 Apr 2. doi: 10.7326/J24-0013. Online ahead of print.ABSTRACTFujiwara Y, Horita N, Adib E, et al. Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials. Lancet Oncol. 2024;25:62-75. 38012893.PMID:38560904 | DOI:10.7326/J24-0013
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Source Type: research